FDA Clearance Impact: Recent chatter on X about Tempus AI, Inc. (TEM) has surged following the company's FDA 510(k) clearance for its RNA-based diagnostic device. Many users see this as a major step forward in precision medicine, sparking excitement about potential growth. The news has fueled discussions on the stock’s trajectory in the AI healthcare space.
Technical and Fundamental Buzz: Posts on X also highlight TEM’s strong technical setup, with some pointing to breakout patterns and high short interest as catalysts. Others note fundamental strengths like revenue growth and upcoming earnings as reasons for optimism. The blend of AI innovation and market dynamics keeps the conversation lively.
Note: This discussion summary was generated from an AI condensation of post data.
Tempus AI, Inc. Insider Trading Activity
Tempus AI, Inc. insiders have traded $TEM stock on the open market 113 times in the past 6 months. Of those trades, 0 have been purchases and 113 have been sales.
Here’s a breakdown of recent trading of $TEM stock by insiders over the last 6 months:
- ERIC P LEFKOFSKY (CEO and Chairman) has made 0 purchases and 54 sales selling 1,697,960 shares for an estimated $127,413,901.
- RYAN FUKUSHIMA (Chief Operating Officer) has made 0 purchases and 20 sales selling 85,280 shares for an estimated $5,610,400.
- THEODORE LEONSIS has made 0 purchases and 3 sales selling 64,770 shares for an estimated $4,643,220.
- ERIK PHELPS (EVP & Chief Admin & Legal Off) has made 0 purchases and 8 sales selling 63,396 shares for an estimated $4,529,084.
- JAMES WILLIAM ROGERS (Chief Financial Officer) has made 0 purchases and 9 sales selling 30,649 shares for an estimated $2,024,803.
- ANDREW POLOVIN (EVP and General Counsel) has made 0 purchases and 9 sales selling 24,373 shares for an estimated $1,619,008.
- RYAN M BARTOLUCCI (Chief Accounting Officer) has made 0 purchases and 5 sales selling 7,977 shares for an estimated $526,163.
- JENNIFER A DOUDNA has made 0 purchases and 2 sales selling 1,183 shares for an estimated $69,876.
- DAVID R EPSTEIN has made 0 purchases and 3 sales selling 870 shares for an estimated $52,619.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Tempus AI, Inc. Hedge Fund Activity
We have seen 39 institutional investors add shares of Tempus AI, Inc. stock to their portfolio, and 23 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAILLIE GIFFORD & CO removed 2,401,588 shares (-19.9%) from their portfolio in Q3 2025, for an estimated $193,832,167
- SUMITOMO MITSUI TRUST GROUP, INC. removed 406,846 shares (-10.5%) from their portfolio in Q3 2025, for an estimated $32,836,540
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 51,169 shares (-11.6%) from their portfolio in Q3 2025, for an estimated $4,129,849
- UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH added 45,786 shares (+147.7%) to their portfolio in Q3 2025, for an estimated $3,695,388
- SG AMERICAS SECURITIES, LLC removed 15,137 shares (-29.0%) from their portfolio in Q3 2025, for an estimated $1,221,707
- NORTHWESTERN UNIVERSITY removed 14,033 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $891,656
- NWF ADVISORY SERVICES INC. added 11,229 shares (+inf%) to their portfolio in Q3 2025, for an estimated $906,292
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Tempus AI, Inc. Government Contracts
We have seen $18,460,020 of award payments to $TEM over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- ADAPT CRO SUPPORT SERVICES SOLICITATION: $12,741,975
- TUMOR NORMAL MATCHED GENOMIC TESTING SERVICES: $5,718,045
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Tempus AI, Inc. Analyst Ratings
Wall Street analysts have issued reports on $TEM in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 10/22/2025
- Guggenheim issued a "Buy" rating on 09/26/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/02/2025
- Morgan Stanley issued a "Overweight" rating on 08/12/2025
To track analyst ratings and price targets for Tempus AI, Inc., check out Quiver Quantitative's $TEM forecast page.
Tempus AI, Inc. Price Targets
Multiple analysts have issued price targets for $TEM recently. We have seen 7 analysts offer price targets for $TEM in the last 6 months, with a median target of $96.0.
Here are some recent targets:
- David Westenberg from Piper Sandler set a target price of $105.0 on 10/22/2025
- Mark Massaro from BTIG set a target price of $96.0 on 10/22/2025
- Kyle Mikson from Canaccord Genuity set a target price of $110.0 on 10/20/2025
- Subbu Nambi from Guggenheim set a target price of $95.0 on 09/26/2025
- Yi Chen from HC Wainwright & Co. set a target price of $98.0 on 09/12/2025
- Tejas Savant from Morgan Stanley set a target price of $68.0 on 08/12/2025
- Michael Ryskin from B of A Securities set a target price of $70.0 on 06/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
